Curcumin,a potent anti-tumor reagent,is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation

被引:0
|
作者
Hong-li LIU~2
机构
基金
中国国家自然科学基金;
关键词
curcumin; histone deacetylase; acetylated histone H4; Raji;
D O I
暂无
中图分类号
R733.1 [网状内皮系统肿瘤];
学科分类号
100214 ;
摘要
Aim:To investigate curcumin(diferuloylmethane)induced apoptosis and its mo-lecular mechanism of action in B-NHL cell line Raji cells.Methods:Raji cells werecultured in RPMI-1640 medium and treated with curcumin in different concentra-tions.3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium(MTT)assay wasused to detect growth inhibition and Hoechst 33258 staining was used to detectapoptosis.Immunocytochemistry and Western blot were used to detect the ex-pressions of histone deacetylase 1,3,and 8(HDAC 1,HDAC3,and HDACS)andacetylated histone H4(Ac-histone H4)protein.Results:Curcumin inhibited theproliferation of B-NHL cell line Raji cells with a 36-h IC50value of 24.1±2.0μmol/L.Hoechst 33258 staining showed that curcumin could induce Raji cell apoptosis.The expression levels of HDAC1,HDAC3,and HDAC8 proteins were downregulat-ed following curcumin treatment in Raji cells,whereas Ac-histone H4 protein expres-sion was upregulated after treatment with curcumin.Conclusion:Curcumin,as anew member of the histone deacetylase inhibitors,can inhibit the expression ofclass I HDACs(HDAC1,HDAC3,and HDAC8),and can increase the expressionof Ac-histone H4 in Raji cells.Curcumin plays an important role in regulatingB-NHL cell line Raji cell proliferation and apoptosis.
引用
收藏
页码:603 / 609
页数:7
相关论文
共 50 条
  • [21] The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL
    A M Savino
    J Sarno
    L Trentin
    M Vieri
    G Fazio
    M Bardini
    C Bugarin
    G Fossati
    K L Davis
    G Gaipa
    S Izraeli
    L H Meyer
    G P Nolan
    A Biondi
    G Te Kronnie
    C Palmi
    G Cazzaniga
    Leukemia, 2017, 31 : 2365 - 2375
  • [22] The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL
    Savino, A. M.
    Sarno, J.
    Trentin, L.
    Vieri, M.
    Fazio, G.
    Bardini, M.
    Bugarin, C.
    Fossati, G.
    Davis, K. L.
    Gaipa, G.
    Izraeli, S.
    Meyer, L. H.
    Nolan, G. P.
    Biondi, A.
    Kronnie, G. Te
    Palmi, C.
    Cazzaniga, G.
    LEUKEMIA, 2017, 31 (11) : 2365 - 2375
  • [23] The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines
    Gahr, Susanne
    Peter, Gisela
    Wissniowski, Thadaus Till
    Hahn, Eckhart G.
    Herold, Christoph
    Ocker, Matthias
    ONCOLOGY REPORTS, 2008, 20 (05) : 1249 - 1256
  • [24] FCN-338, a novel and selective Bcl-2 inhibitor, exhibits potent anti-tumor activity in B-cell lymphoma
    Lin, Shu
    Zhao, Xingdong
    Liu, Hongbin
    Zhang, Huajie
    Chen, Zhifang
    Jiang, Lihua
    Liu, Yanxin
    Lin, Min
    Rong, Yue
    Tan, Rui
    Zhou, Zuwen
    Zou, Zongyao
    Gao, Yuwei
    Wang, Weibo
    CANCER RESEARCH, 2019, 79 (13)
  • [25] Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma
    Kim, Soo Jin
    Kim, U. Ji
    Yoo, Hae Yong
    Choi, Yong June
    Kang, Keon Wook
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (12) : 1 - 12
  • [26] Deguelin, an Aurora B Kinase Inhibitor, Exhibits Potent Anti-Tumor Effect in Human Esophageal Squamous Cell Carcinoma
    Yu, Xinfang
    Liang, Qi
    Liu, Wenbin
    Zhou, Li
    Li, Wei
    Liu, Haidan
    EBIOMEDICINE, 2017, 26 : 100 - 111
  • [27] Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-Tumor Activity in B-Cell Malignancies
    Thompson, Peggy A.
    Eam, Boreth
    Young, Nathan P.
    Fish, Sarah
    Chen, Joan
    Barrera, Maria
    Howard, Haleigh
    Parra, Ana
    Molter, Jolene
    Staunton, Jocelyn
    Hung, Ivy N. J.
    Parker, Greg S.
    Chiang, Gary G.
    Wegerski, Chris J.
    Nevarez, Andres
    Clarine, Jeff
    Sperry, Sam
    Xiang, Alan
    Tran, Chinh
    Nilewski, Christian
    Packard, Garrick K.
    Michels, Theodore
    Sprengeler, Paul A.
    Ernst, Justin T.
    Reich, Siegfried H.
    Webster, Kevin R.
    BLOOD, 2017, 130
  • [28] Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation
    Kato, Yukihiko
    Egusa, Chizu
    Maeda, Tatsuo
    Tsuboi, Ryoji
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2016, 81 (01) : 17 - 25
  • [29] Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation
    Kato, Y.
    Egusa, C.
    Maeda, T.
    Tsuboi, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (05) : S16 - S16
  • [30] Novel synthetic histone deacetylase inhibitor, SK-7041, has potent anti-proliferative activity in acute myeloid leukemia cell lines
    Yoon, Sung-Soo
    Bae, Eunkyung
    Park, Juwon
    Cha, Yongjun
    Lee, Young Y.
    Kim, Byoung K.
    BLOOD, 2007, 110 (11) : 839A - 839A